The global Cardiac Biomarkers market was valued at USD 7.96 Billion in 2020 and is expected to reach USD 17.55 Billion by year 2028, at a CAGR of 10.4%.
According to the Centre for Disease Control and Prevention (CDC), for around 610,000 people die of heart disease in United States every year, that’s 1 in every 4 deaths and more than half of the deaths due to heart disease were in men. Cardiac biomarkers are protein-based observable materials discharged into blood when the heart’s muscles are wounded which can be used as risk stratification for numerous cardiovascular diseases (CVDs) that includes Acute Myocardial Infarction (AMI), Ischemia, Congestive Heart Failure (CHF), Acute Coronary Syndrome (ACS) and others related with insufficient blood flow to heart.
The high occurrence rates of CVDs worldwide and the growing demand for POC cardiac testing kits are expected to fuel the market growth. Certain manufacturing, limited specificity and pharmacological issues and regulatory hurdles are hindering the growth of the market.
Development of products from leading companies has been propelling the growth of this market. In July 2020, FDA cleared Siemens Healthineers high-sensitivity troponin I assays (TnIH) for Atellica IM and ADIVA Centaur XP/XPT in vitro disnostic analyzers from Siemens Healthineers to speed up the time for detection of diagnosis of myocardial infarctions.
Top Companies Profiled in the Report Include:
Abbott Laboratories, Alere Inc. and Roche Diagnostics Corporation.
Get a sample of the report @ URL https://www.reportsanddata.com/sample-enquiry-form/1422
The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1422
The report has gather vital information about recent mergers and acquisitions, joint ventures, collaborations, partnerships, brand promotions, R&D activities, and government and corporate deals, among others through extensive primary and secondary research. The report also offers detailed analysis of each competitor along with their financial standing, global market position, product portfolio, manufacturing and production capacity, and business expansion plans.
To know more about the report @ https://www.reportsanddata.com/press-release/global-cardiac-biomarkers-market
Additionally, the report consists a detailed analysis of the segmentation of the Cardiac Biomarkers market based on product types and end-use/application offered in the Cardiac Biomarkers market.
Product Type (Revenue, USD Million; 2020–2028)
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Troponins (T and I)
- Myocardial muscle Creatine Kinase (CK-MB)
Location of Testing (Revenue, USD Million; 2020–2028)
- Laboratory Testing
- Point of Care Testing
Application (Revenue, USD Million; 2020–2028)
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
End User (Revenue, USD Million; 2020–2028)
- Diagnostic Laboratories
- Hospitals and Clinics
The report offers a comprehensive overview of the regional bifurcation of the market with respect to market share, market size, revenue growth, import/export, production and consumption patterns, macro and micro economic growth factors, regulatory framework, investment and funding opportunities, and presence of key players in each region including North America, Asia Pacific, Latin America, Europe, and Middle East & Africa. The report offers a country-wise analysis to further discuss the revenue growth and lucrative growth opportunities for the Cardiac Biomarkers market in these key regions.
Country-wise regional analysis covers:
- North America
- Latin America
- Middle East & Africa
Read More Reports
Thank you for reading our report. For customization inquiry or further information, please connect with us and we will ensure you get the report that meets your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370